References
- Kay J, Rahman MU. Golimumab: a novel anti-TNF-alpha monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. Core Evid 2009;4:159-70
- Zhou H, Jang H, Fleischmann RM, et al. Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis. J Clin Pharmacol 2007;47:383-96
- Xu Z, Wang Q, Zhuang Y, et al. Subcutaneous bioavailability of golimumab at 3 different injection sites in healthy subjects. J Clin Pharmacol 2010;50:276-84
- Zhuang Y, Xu Z, Frederick B, et al. Golimumab pharmacokinetics after repeated subcutaneous and intravenous administration in patients with rheumatoid arthritis and the effect of concomitant methotrexate: an open-label, randomized study. Clin Ther 2012;34:77-90
- Kay J, Matteson EL, Dasgupta B, et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose ranging study. Arthritis Rheum 2008;58:964-75
- Emery P, Fleischmann RM, Moreland LH, et al. Golimumab, a human anti-tumour necrosis factor-alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate naïve patients with active rheumatoid arthritis: 24 week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum 2010;60:2272-83
- Emery P, Fleischmann RM, van der Heijde D, et al. The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized, controlled studies of golimumab before methotrexate therapy and after methotrexate therapy. Arthritis Rheum 2011;63:1200-10
- Keystone EC, Genevese MC, Klareskog L, et al. Golimumab, a human antibody to tumour necrosis factor-alpha given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD study. Ann Rheum Dis 2009;68:789-96
- Smolen JS, Kay J, Doyle MK, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor-alpha inhibitors (GO-AFTER study): a multi-centre, randomized, double-blind, placebo-controlled, phase III trial. Lancet 2009;374:210-21
- Kavanaugh A, van der Heijde D, McInnes IB, et al. Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. Arthritis Rheum 2012;64:2504-17
- Inman RD, Davis JC Jr, van der Heijde D, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 2008;58:3402-12
- Kremer J, Ritchlin C, Mendelsohn A, et al. Golimumab, a new human anti-tumor necrosis factor-alpha antibody, administered intravenously in patients with active rheumatoid arthritis: forty-eight week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study. Arthritis Rheum 2010;62:917-28
- Weinblatt ME, Bingham COIII, Mendelsohn AM, et al. Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomized, multicentre, double-blind, placebo-controlled GO-FURTHER trial. Ann Rheum Dis 2013;72:381-9
- Weinblatt ME, Westhovens R, Mendelsohn A, et al. Radiographic benefit and maintenance of clinical benefit with intravenous golimumab therapy in patients with active rheumatoid arthritis despite methotrexate therapy: results up to 1 year of the phase 3, randomized, multicentre, double-blind, placebo controlled GO-FURTHER trial. Ann Rheum Dis 2013. [Epub ahead of print]
- Taylor PC, Ritchlin C, Mendelsohn A, et al. Maintenance of efficacy and safety with subcutaneous golimumab among patients with active rheumatoid arthritis who previously received intravenous golimumab. J Rheumatol 2011;38:2572-80
- Heimans L, van den Broek M, le Cesie S, et al. Association of high body mass index with decreased response to combination therapy in recent-onset rheumatoid arthritis patients. Arthritis Care Res 2013;65:1235-42